Patents by Inventor Nancy Tich

Nancy Tich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATMENT OF OSTEOARTHRITIS WITH TRANSDERMAL CANNABIDIOL GEL
    Publication number: 20240148669
    Abstract: A pharmaceutical composition, and methods for using a pharmaceutical composition, for treating osteoarthritis in a subject in need thereof, the pharmaceutical composition including cannabidiol or a pharmaceutically acceptable salt thereof; and especially wherein administration of the cannabidiol is by a transdermal pharmaceutical gel composition. A method is disclosed for treating one or more symptoms of osteoarthritis in a patient. The method includes transdermally administering an effective amount of cannabidiol (CBD) to the patient wherein one or more symptoms of osteoarthritis are treated in the patient.
    Type: Application
    Filed: October 6, 2023
    Publication date: May 9, 2024
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Nancy Tich, John Messenheimer, Donna Gutterman, Daniel Clauw, Ted Smith, James Griesser
  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20230414533
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Application
    Filed: August 30, 2023
    Publication date: December 28, 2023
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • Treatment of Fragile X Syndrome with cannabidiol
    Patent number: 11779549
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Grant
    Filed: August 24, 2022
    Date of Patent: October 10, 2023
    Assignee: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20230000790
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Application
    Filed: August 24, 2022
    Publication date: January 5, 2023
    Applicants: ZYNERBA PHARMACEUTICALS, INC., ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • Treatment of Fragile X Syndrome with cannabidiol
    Patent number: 11458110
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: October 4, 2022
    Assignee: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • TREATMENT OF FRAGILE X SYDROME WITH CANNABIDIOL
    Publication number: 20200360299
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Application
    Filed: August 6, 2020
    Publication date: November 19, 2020
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • Treatment of fragile x syndrome with cannabidiol
    Patent number: 10758497
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: September 1, 2020
    Assignee: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • METHODS OF TREATMENT OF OSTEOARTHRITIS WITH TRANSDERMAL CANNABIDIOL GEL
    Publication number: 20200170963
    Abstract: A pharmaceutical composition, and methods for using a pharmaceutical composition, for treating osteoarthritis in a subject in need thereof, the pharmaceutical composition including cannabidiol or a pharmaceutically acceptable salt thereof; and especially wherein administration of the cannabidiol is by a transdermal pharmaceutical gel composition. A method is disclosed for treating one or more symptoms of osteoarthritis in a patient. The method includes transdermally administering an effective amount of cannabidiol (CBD) to the patient wherein one or more symptoms of osteoarthritis are treated in the patient.
    Type: Application
    Filed: February 12, 2020
    Publication date: June 4, 2020
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Nancy Tich, John Messenheimer, Donna Gutterman, Daniel Clauw
  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20200030255
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Application
    Filed: October 7, 2019
    Publication date: January 30, 2020
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • Treatment of fragile X syndrome with cannabidiol
    Patent number: 10471022
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: November 12, 2019
    Assignee: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20190167605
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Application
    Filed: January 16, 2019
    Publication date: June 6, 2019
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • Treatment of fragile X syndrome with cannabidiol
    Patent number: 10213390
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: February 26, 2019
    Assignee: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree